Pfizer’s Lung Cancer Treatment Combination Signed Off by FDA

The US FDA has acknowledged the BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) sNDAs (Supplemental New Drug Applications) combination for evaluation, according to Pfizer.

The duo is designed to treat individuals with metastatic non-small cell lung cancer (NSCLC) who have the BRAF V600E mutation. The condition must have been determined using an assay which has been cleared for use by the FDA.

The BRAFTOVI and MEKTOVI combination is already authorised in the US for use in the medical care of those who have specific mutations of metastatic or unresectable melanoma.

BRAFTOVI has been signed off for use alongside cetuximab for metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as long as the patient is over 18 years of age and the condition was determined using an assay which has been cleared for use by the FDA.

Chief Development Officer of Oncology and Rare Disease at Pfizer, Chris Boshoff, explained that “since their initial regulatory approvals, BRAFTOVI and MEKTOVI have helped improve outcomes in their respective indications of BRAF-mutated metastatic melanoma and BRAF-mutated metastatic colorectal cancer. The combination has shown the potential to help more patients, such as those living with BRAF V600E-mutant non-small cell lung cancer.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.